Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1451"
| Predicate | Value (sorted: default) |
|---|
| rdfs:label |
|
| rdf:type |
|
| ?:Evidence_enzyme_system |
|
| ?:Evidence_type |
|
| ?:content |
"Approximately 7% of the normal population has a genetic defect that leads to reduced levels of activity of cytochrome P450IID6 isozyme. Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in thirteen PM subjects demonstrated altered pharmacokinetic properties compared to sixteen "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by IID6 isozyme. Caution is indicated in patients known to have reduced levels of P450IID6 activity and those receiving concomitant drugs known to inhibit this isozyme (e.g., quinidine)."
|
| dc:creator |
|
| dc:date |
|
| rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ fluvoxamine_is_not_substrate_of_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1671 }
Context graph
